Akebia Drug Patent Portfolio

Akebia owns 1 orange book drug protected by 13 US patents Given below is the list of Akebia's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11324734 Compositions and methods for treating anemia 31 Mar, 2036
Active
US11844756 Compositions and methods for treating anemia 31 Mar, 2036
Active
US10149842 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof 14 Nov, 2034
Active
US11065237 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof 14 Nov, 2034
Active
US9701636 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof 14 Nov, 2034
Active
US9987262 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof 14 Nov, 2034
Active
US11857543 Compositions and methods for treating anemia 09 Jun, 2034
Active
US8323671 Prolyl hydroxylase inhibitors and methods of use 03 Apr, 2028
Active
US7811595 Prolyl hydroxylase inhibitors and methods of use 13 Mar, 2028
Active
US8343952 Prolyl hydroxylase inhibitors and methods of use 14 Aug, 2027
Active
US8598210 Prolyl hydroxylase inhibitors and methods of use 26 Jun, 2027
Active
US8940773 Prolyl hydroxylase inhibitors and methods of use 26 Jun, 2027
Active
USRE47437 Prolyl hydroxylase inhibitors and methods of use 26 Jun, 2027
Active


Given below is the list of recent legal activities going on the following drug patents of Akebia.

Activity Date Patent Number
Patent litigations
Mail Patent eCofC Notification 11 Jun, 2024 US8940773
Patent eCofC Notification 11 Jun, 2024 US8940773
Recordation of Patent eCertificate of Correction 11 Jun, 2024 US8940773
Email Notification 11 Jun, 2024 US8940773
Post Issue Communication - Certificate of Correction 21 May, 2024 US8940773
Initial letter Re: PTE Application to regulating agency 21 May, 2024 US8940773
Patent Term Extension Application under 35 USC 156 Filed 17 May, 2024 US8343952 (Litigated)
Patent Term Extension Application under 35 USC 156 Filed 17 May, 2024 US7811595 (Litigated)
Patent Term Extension Application under 35 USC 156 Filed 17 May, 2024 US8598210 (Litigated)
Patent Term Extension Application under 35 USC 156 Filed 17 May, 2024 US8940773
Patent Term Extension Application under 35 USC 156 Filed 17 May, 2024 US8323671 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 15 May, 2024 US8343952 (Litigated)
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 15 May, 2024 US8323671 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 15 May, 2024 US8323671 (Litigated)
Email Notification 02 Jan, 2024 US11857543


Akebia's Family Patents


Family Patents



Akebia Drug List

Given below is the complete list of Akebia's drugs and the patents protecting them.


1. Vafseo

Vafseo is protected by 13 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11324734 Compositions and methods for treating anemia 31 Mar, 2036
(11 years from now)
Active
US11844756 Compositions and methods for treating anemia 31 Mar, 2036
(11 years from now)
Active
US10149842 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof 14 Nov, 2034
(10 years from now)
Active
US11065237 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof 14 Nov, 2034
(10 years from now)
Active
US9701636 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof 14 Nov, 2034
(10 years from now)
Active
US9987262 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof 14 Nov, 2034
(10 years from now)
Active
US11857543 Compositions and methods for treating anemia 09 Jun, 2034
(9 years from now)
Active
US8323671 Prolyl hydroxylase inhibitors and methods of use 03 Apr, 2028
(3 years from now)
Active
US7811595 Prolyl hydroxylase inhibitors and methods of use 13 Mar, 2028
(3 years from now)
Active
US8343952 Prolyl hydroxylase inhibitors and methods of use 14 Aug, 2027
(2 years from now)
Active
US8598210 Prolyl hydroxylase inhibitors and methods of use 26 Jun, 2027
(2 years from now)
Active
US8940773 Prolyl hydroxylase inhibitors and methods of use 26 Jun, 2027
(2 years from now)
Active
USRE47437 Prolyl hydroxylase inhibitors and methods of use 26 Jun, 2027
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vafseo's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List